8-K: Salarius Pharma Believes It Regains Nasdaq Equity Compliance

Salarius Pharmaceuticals, Inc. announced it believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement after raising $6.2 million through recent stock sales.

Summary

• Salarius Pharmaceuticals, Inc. (SLRX) believes it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity for continued listing.
• The company had a deadline of October 20, 2025, to achieve this compliance.
• Since June 30, 2025, the company raised an aggregate of $6.2 million in gross proceeds through two separate stock offerings.
• This includes $2.4 million from the sale of 434,882 shares via an At the Market Offering Agreement and $3.8 million from the sale of 367,887 shares through a Securities Purchase Agreement.
• The company anticipates its Quarterly Report on Form 10-Q for the period ended September 30, 2025, will reflect stockholders' equity exceeding $2.5 million.
• The current determination of stockholders' equity is an estimate, not audited, reviewed, or compiled by an independent accounting firm, and is subject to change upon completion of financial closing procedures.
• The company is awaiting Nasdaq's official confirmation of compliance.

Sentiment

Score: 7

Explanation: The company has taken decisive steps to address its Nasdaq listing compliance issue by successfully raising significant capital. While the compliance is based on preliminary estimates and awaits official Nasdaq confirmation, the proactive measures and the company's belief in achieving the required equity level are positive indicators. The inherent risks of non-compliance and the preliminary nature of the financial data temper the overall sentiment slightly.

Positives

• The company believes it has achieved the minimum $2.5 million stockholders' equity required by Nasdaq.
• Successfully raised $6.2 million in gross proceeds through stock sales since June 30, 2025, bolstering its financial position.
• Anticipates reflecting stockholders' equity in excess of $2.5 million in the upcoming Q3 2025 Form 10-Q.

Negatives

• Compliance is based on preliminary estimates and has not been audited, reviewed, or compiled by an independent accounting firm.
• Financial closing procedures for Q3 2025 are not yet complete, and final stockholders' equity may vary from the preliminary estimate.
• Awaits Nasdaq's official confirmation, indicating compliance is not yet finalized and carries inherent uncertainty.

Risks

• History of noncompliance with Nasdaq listing standards.
• Absence of any guarantee against future noncompliance.
• Risk of not being successful in remedying future noncompliance.
• Potential delisting of common stock from The Nasdaq Capital Market.
• Correlative loss of market value and liquidity of the common stock if delisted.

Future Outlook

The company anticipates that its Quarterly Report on Form 10-Q for the period ended September 30, 2025, will reflect stockholders' equity in excess of $2.5 million. It also expects its stockholders' equity to continue to exceed $2.5 million at future dates, pending Nasdaq's official confirmation of compliance.

Management Comments

• "The Company believes that, as a result of the transactions described above, as of the date of this Current Report on Form 8-K, the Company’s stockholders’ equity exceeds $2.5 million."
• "The Company anticipates that the information contained in its Quarterly Report on Form 10-Q for the period ended September 30, 2025 will reflect stockholders’ equity in excess of $2.5 million as of September 30, 2025."
• "The Company awaits Nasdaq’s confirmation that the Company has successfully evidenced this compliance."

Industry Context

In the biotechnology and pharmaceutical industry, maintaining Nasdaq listing standards is crucial for access to capital and investor visibility. Companies often utilize "At the Market" (ATM) offerings and private placements to raise capital, especially when facing compliance issues or funding ongoing research and development. This filing reflects a common strategy for smaller biotech firms to shore up their balance sheets and maintain their public listing status.

Comparison to Industry Standards

• Maintaining minimum stockholders' equity is a standard requirement across major stock exchanges for publicly traded companies, ensuring a baseline of financial stability.
• The use of ATM offerings and private placements (like the Securities Purchase Agreement) are common capital-raising mechanisms for development-stage biotechnology companies, particularly when market conditions or company-specific factors make traditional equity offerings challenging.
• While the specific financial metrics are company-specific, the action of raising capital to meet listing requirements is a standard practice for companies in similar situations.

Stakeholder Impact

• Shareholders: Potential positive impact from maintaining Nasdaq listing, which preserves liquidity and market visibility. Dilution from recent stock sales.
• Investors: Provides clarity on the company's efforts to maintain its listing, reducing uncertainty.
• Nasdaq: Awaits confirmation of compliance.

Next Steps

• Complete financial closing procedures for the quarter ended September 30, 2025.
• File the Quarterly Report on Form 10-Q for the period ended September 30, 2025.
• Await Nasdaq's official confirmation of compliance with the Equity Standard.

Key Dates

Recommendation

While Salarius Pharmaceuticals has taken positive steps to address its Nasdaq listing compliance by raising capital and believes it has met the equity requirement, the situation remains preliminary. The compliance is based on unaudited estimates and awaits official confirmation from Nasdaq. Furthermore, the company has a history of noncompliance, and future risks of delisting and loss of market value persist. Investors should hold until Nasdaq's confirmation is received and the audited Q3 10-Q is released, providing a clearer picture of the company's financial standing and long-term stability. The capital raises also imply dilution, which needs to be factored in.

Keywords

Salarius Pharmaceuticals, SLRX, Nasdaq compliance, stockholders equity, capital raise, equity offering, biotechnology, pharmaceuticals, SEC filing, 8-K, listing standards, financial reporting